Back to search

Article

Efficacy of N-163 strain of<i>Aureobasidium pullulans</i>-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trial

2023-05-02

Abstract excerpt

Duchenne muscular dystrophy (DMD) is a debilitating genetic disease that causes gradual muscle weakening and early mortality. After a 45-day clinical pilot study and a pre-clinical study in mdx mice demonstrating safety and efficacy, and anti-fibrotic and anti-inflammatory effects, respectively, of an Aureobasidium pullulans N-163 strain-produced B-1,3–1,6-glucan. We conducted this linear six-month clinical study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8147f5e9-5731-55ed-a9af-902b1ec04aa8
DOI
10.1101/2023.04.29.23289260
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of N-163 strain of<i>Aureobasidium pullulans</i>-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trialDOI 10.1101/2023.04.29.23289260
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of <i>Aureobasidium pullulans</i> produced biological response modifier β-glucan (BRMG)Semantic proximity
Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to muscle function in patients with muscular dystrophies in a pilot clinical studySemantic proximity
Enhanced expression of Dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including Diaphragm of <i>mdx</i> mice after oral administration of Neu REFIX Beta 1,3-1,6 glucanSemantic proximity
Reduction in myocardial fibrosis in MDX mice on oral consumption of <i>Aureobasidium Pullulans</i> produced Neu REFIX Beta-glucans; holds potential as an adjuvant in managing post-transplantation organ fibrosisSemantic proximity
Muscular Dystrophies and Therapeutic Potential of Medicinal PlantsSemantic proximity
Nutritional intervention with cyanidin hinders the progression of muscular dystrophy.Semantic proximity
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 TrialSemantic proximity
Generation and Characterization of <i>Col6a1</i> knock-in mice: A Promising Pre-Clinical Model for Collagen VI-Related DystrophiesSemantic proximity
A Potential Beta-hydroxybutyrate Therapy for Duchenne Muscular Dystrophy in Disease ModelsSemantic proximity
GBT1118 voxelotor analog improves skeletal muscle function, phenotype and significantly reduced serum myopathy biomarker GDF15 in sickle cell disease mice.Semantic proximity
Deficiency of the commensal Bacteroides vulgatus exacerbates skeletal muscle damage in mouse and human models of Duchenne Muscular DystrophySemantic proximity
Hydrogen-Oxygen Nanobubble Therapy as a Complementary Approach in a Female Patient with Duchenne Muscular Dystrophy (DMD): A Case ReportSemantic proximity
Select a neighboring publication to make it the new centre.